By Dean Seal
Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell lung cancer.
The stock was up 12% at $2.10 in premarket trading. Shares had fallen 22% year-to-date when the market closed Wednesday.
The biotechnology company said before the bell that mature survival data for patients treated with the combination were well above historical controls and exceeded expectations.
"We are encouraged to see Efti build upon the historical clinical outcomes from the most widely used immunotherapy-chemo combination today," Chief Executive Marc Voigt said.
Early evaluations of an expanded cohort of trial patients are also tracking well, Voigt said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
November 14, 2024 09:10 ET (14:10 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。